June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Short term Efficacy of intravitreal dexamethasone implant in patients with macular edema (ME) secondary to vascular retinal diseases
Author Affiliations & Notes
  • matteo federici
    OPHTHALMOLOGY, catholic university of sacred hearth, Roma, italy, Italy
  • VALERIA PAGLIEI
    OPHTHALMOLOGY, catholic university of sacred hearth, Roma, italy, Italy
  • angela lanza
    OPHTHALMOLOGY, catholic university of sacred hearth, Roma, italy, Italy
  • MARIA CRISTINA SAVASTANO
    OPHTHALMOLOGY, catholic university of sacred hearth, Roma, italy, Italy
  • Giulia Midena
    OPHTHALMOLOGY, catholic university of sacred hearth, Roma, italy, Italy
  • Benedetto Falsini
    OPHTHALMOLOGY, catholic university of sacred hearth, Roma, italy, Italy
  • ANGELO MARIA MINNELLA
    OPHTHALMOLOGY, catholic university of sacred hearth, Roma, italy, Italy
  • aldo caporossi
    OPHTHALMOLOGY, catholic university of sacred hearth, Roma, italy, Italy
  • Footnotes
    Commercial Relationships   matteo federici, None; VALERIA PAGLIEI, None; angela lanza, None; MARIA CRISTINA SAVASTANO, None; Giulia Midena, None; Benedetto Falsini, None; ANGELO MARIA MINNELLA, None; aldo caporossi , None
  • Footnotes
    Support  i do not use a grant
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4677. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      matteo federici, VALERIA PAGLIEI, angela lanza, MARIA CRISTINA SAVASTANO, Giulia Midena, Benedetto Falsini, ANGELO MARIA MINNELLA, aldo caporossi; Short term Efficacy of intravitreal dexamethasone implant in patients with macular edema (ME) secondary to vascular retinal diseases
      . Invest. Ophthalmol. Vis. Sci. 2017;58(8):4677.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Purpose: To evaluate prospectively the short term efficacy of intravitreal dexamethasone implant (IDI) in patients with macular edema (ME) measuring central macular thickness (CMT) and visual acuity modification up to one month. Secondary endpoints were the evaluation of choroidal thickness and the safety of the drug in terms of intraocular pressure and other ocular and systemic side effects.

Methods : Methods: In this prospective study, the authors observed 15 consecutive patients affected by retinal vascular diseases (diabetes, retinal vein occlusion) and macular edema (central macular thickness more than 300μ) treated by intravitreal injection of long release intravitreal dexamethasone (Ozurdex ™). Fifteen eyes of 15 consecutive patients were included in the study. Central macular thickness and choroidal thickness were evaluated by enhanced depth optical coherence tomography (EDI-OCT). EDI-OCT, intraocular pressure (IOP) and best correct visual acuity (BCVA) were reported at baseline and after 3, 6, 24 hours, and then after 1 week and 1 month later.

Results : Results: We observed a reduction in CMT since the first measurement, after 3 hours from the injection and progressively continuing along at the next follow up, to one months. Choroidal thicknesses showed no significant changes from the baseline visit to the last follow up 1 month later post-injection (P > 0.05). Visual acuity gain shows a correlation with the reduction of CMT. We found a significant increase of BCVA after 3, 24 hours, 1 and 4 weeks of treatment. One month after IDI, CRT was 296,7 ± 109,9 and was significantly lower compared with pretreatment value 506,7 ± 143,1. No significant change in IOP after the treatment was observed. Secondary endpoint: nor systemic neither ocular side effects were noticed.

Conclusions : Conclusion: The reduction in central macular thickness is appreciated as early as 3 hours after the injection of intravitreal Ozurdex with progressively reduction during the follow up of the study (up to one month). Choroidal thickness measurement seemed to be unchanged after IDI from baseline to end of study. No differences was observed between the group of DME and RVO. The study shows the early effect of IDI and it confirms the safety profile of the drug.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×